Outcomes of XEN 63 Device at 18-Month Follow-Up in Glaucoma Patients: A Two-Center Retrospective Study.
Antonio Maria FeaMartina MenchiniAlessandro RossiChiara PosarelliLorenza MalinverniMichele FigusPublished in: Journal of clinical medicine (2022)
The XEN63, either alone or in combination with cataract surgery, significantly lowered the IOP and reduced the need for ocular hypotensive drugs over a period of 18 months.